Home LiteratureArticle Details
PMID: 9717952 Published · ppublish English Comment Comparative Study Letter

Tamoxifen in early breast cancer.

Lancet (London, England) ·Vol. 352 ·No. 9125 ·1998-08-01 ·Pages 403

Bryce CJ

Abstract

暂无摘要

MeSH Terms
Age Factors Antineoplastic Agents, Hormonal/administration & dosage,therapeutic use Breast Neoplasms/drug therapy,pathology Estrogen Antagonists/administration & dosage,therapeutic use Female Follow-Up Studies Humans Menopause Middle Aged Neoplasm Staging Placebos Receptors, Estrogen/analysis Risk Factors Tamoxifen/administration & dosage,therapeutic use
Chemicals
Antineoplastic Agents, Hormonal Estrogen Antagonists Placebos Receptors, Estrogen Tamoxifen
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Bryce C J
Article Info
Journal
Lancet (London, England)
Abbr.
Lancet
ISSN
0140-6736
DOI
10.1016/S0140-6736(05)60500-4
Published
1998-08-01
Pages
403
Language
English
Region
England
NLM ID
2985213R
Subset
IM
Corrections
CommentOn
PMID: 9605801
External Links
PubMed source DOI: 10.1016/S0140-6736(05)60500-4 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2